Introduction: First-episode mania (FEM) is the first feasible diagnostic and therapeutic opportunity. Lithium is established as a first-line treatment for bipolar disorder. More recently antipsychotic drugs including quetiapine have been found to be effective in the treatment of mania, depression and in maintenance. However, the comparative benefits of these agents in the maintenance phase after a first episode of mania are unclear. This study compared the differential clinical effect of Lithium and Quetiapine after a first episode of mania. Method: The study was a single-blind, randomised controlled trial of 61 participants in remission from a first episode of severe mania. Participants were stabilised on the combination of lithium or quetiapine and were then randomised to either agent as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive clinical battery including mood, functioning, psychotic and quality of life measures conducted at baseline, month 3 and month 12 follow-up time-points. Results: At endpoint, there was an advantage for lithium over quetiapine on measures of depression, psychosis and global impression. Conclusion: This study suggests that in a group of young individuals with a first episode of mania, lithium may have clinical advantages over quetiapine over the maintenance phase. This data is in contrast to some published reports suggesting broad equivalence, and raises questions about stage specific patterns of response as well as differential efficacy in classic severe mania. Abstract Patients with bipolar disorder have impairments in cognitive functioning in several domains that persist even during euthymia. In order to understand the cognitive function trajectory, we assessed cognitive function in bipolar patients after they remitted from the first manic episode and at 6 months to 1 year intervals. Result showed that while cognitive function is impaired as early as after first manic episode remission, those that remain episode free show improvements in cognitive function. Further, in a recent single blind trial, we found that lurasidone adjunctive therapy significantly improved global cognition scores, subjective cognitive complaints and quality of life. These data demonstrate that optimal intervention in early stage bipolar disorder has the potential to reverse cognitive deficits and improve outcomes and that pharmacotherapy can reverse cognitive deficits in bipolar disorder.
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Abstract Patients with bipolar disorder have impairments in cognitive functioning in several domains that persist even during euthymia. In order to understand the cognitive function trajectory, we assessed cognitive function in bipolar patients after they remitted from the first manic episode and at 6 months to 1 year intervals. Result showed that while cognitive function is impaired as early as after first manic episode remission, those that remain episode free show improvements in cognitive function. Further, in a recent single blind trial, we found that lurasidone adjunctive therapy significantly improved global cognition scores, subjective cognitive complaints and quality of life. These data demonstrate that optimal intervention in early stage bipolar disorder has the potential to reverse cognitive deficits and improve outcomes and that pharmacotherapy can reverse cognitive deficits in bipolar disorder. 
Abstract
The concept that blockade of limbic and dorsal striatal dopamine (DA) D 2 receptors is the exclusive basis for the efficacy of all antipsychotic drugs (APDs) to treat positive symptoms is still confidently stated as an unquestionable principle of treating schizophrenia. However, its limitations have been evident ever since the evidence for the contribution of serotonin (5-HT) 2A receptor blockade as a key target of atypical APDs when associated with weaker D 2 receptor blockade was discovered nearly 20 years ago, followed by the demonstration that selective 5-HT 2A inverse agonists, e.g. M100907 and SR43459B, are effective standalone APDs. These findings contributed to the development of pimavanserin, another selective 5-HT 2A inverse agonist) which is expected to be approve for treating L-DOPA psychosis in 2016. Evidence will be presented that pimavanserin can be effective in the treatment of schizophrenia as an augmentation agent for subeffective doses of the atypical APD, risperidone. This general mechanism which can be used to achieve antipsychotic action with minimal weight gain, prolactin elevations and EPS for other atypical APDs. There is also evidence that other 5-HT receptors are targets for APDs, including 5-HT 2C agonism, 5-HT 7 antagonism, and 5-HT 1A receptor partial agonism.
Several atypical APDs with potent 5-HT 2A receptor inverse agonism, including clozapine, olanzapine, risperidone, and lurasidone, are effective to treat positive symptoms in treatment resistant schizophrenia, especially when administered for more than six weeks. It will be shown that a two week trial is not adequate for non-treatment resistant schizophrenia. Atypical APDs are also more effective to treat the cognitive impairment associated with schizophrenia (CIAS) and cause less Parkinsonism and tardive dyskinesia (TD). There is now evidence that TD is associated with worse cognitive impairment and can diminish the ability of atypical APDs to improve CIAS, possibly via restoring grey matter in cortical brain regions. THE atypical APDs enhance the release of growth factors such as BDNF and restore synaptic structure and function in rodent and primate brain. Direct and indirect actions of atypical APDs at DA D 1 , 5-HT 1A , 5-HT 7 , Abstracts | 27 nicotinic and muscarinic receptors have been shown in animal models to contribute to restoring cognitive function in various rodent models of CIAS while excessive D 2 receptor blockade has a negative influence on cognition.
Data from recent GWAS studies will be presented which demonstrate that the efficacy of atypical APDs to improve psychopathology in schizophrenia is mediated by gene products that affect synaptic structure and function, e.g. neurexin and other synaptic adhesion gene products.
The synaptic mechanisms that are required for normal reality testing, rewarded behavior, and higher cognitive function may be impaired by too much or too little stimulation of all five DA receptors, certainly not just D 2 receptors. The atypical APDs are better able to achieve optimal stimulation of these receptors through a variety of mechanisms, many of which are serotonergic. D2 receptor blockade is not necessary but sometimes sufficient which has led to long standing overvaluation of its importance. The heterogeneity in response to APDs may be related to genetic variations which govern the various ways in which synapses can be made to work effectively. Results are ambiguous and the discussion on whether or not an intervention at the stage is justified is ongoing. 2) Following the enhanced understanding of the pathophysiology of schizophrenia, also with respect to specific symptom domains, pharmacological targets beyond D2 receptor antagonism have been explored. Much work and enthusiasm has revolved around nicotinergic and glutamatergic compounds, so far with mostly discouraging results. 3) Several new generation antipsychotics have become available as long-acting depot formulations. All of them have demonstrated a significant positive impact on relapse rates in placebo controlled studies. Whether these compounds also have advantages over first generation depots and / or oral antipsychotics is still debated and investigated.
Lastly, attempts from various perspectives, including genetics and neuroimaging, have investigated whether it is possible to predict treatment response and drug safety. Although some look promising, they have not yet reached a stage in which they can be applied to everyday clinical practice. What has become clear though, is, that early non response predicts late non response, leading to the recommendation to switch antipsychotics much earlier than stated in most treatment guidelines. This presentation will focus on topics 2) and 3).
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Title: The antipsychotic drug deadlock -causes and solutions Abstract It has been a matter of debate for more than a decade whether second-generation antipsychotics (SGAs) represent an advantage over first generation compounds (FGAs). Especially the "effectiveness" studies (CATIE, CUtLASS, EUFEST) could not unequivocally confirm the superiority of SGAs over FGAs. It has been even questioned whether there was any progress in schizophrenia drug treatment since the introduction of clozapine. We have recently demonstrated in the multicentre, randomised, double-blind "Neuroleptic Strategy Study" (NeSSy; Gründer et al., 2016) that quality of life was statistically and clinically significantly more improved with SGAs compared to FGAs, when selection of the antipsychotic was individualised for each specific patient. SGAs might represent a significant advantage in terms of quality of life, as judged by patients. Based on ratings of psychopathology by clinicians, however, SGAs did not differ significantly from FGAs. The randomised, placebo-controlled trial in parallel groups is considered the gold standard for the evaluation of novel pharmaceuticals (Stroup et al., 2006), although this trial design does not take into account the marked patient heterogeneity characterizing schizophrenia nor the profound disparity in the pharmacological profile of antipsychotics. We suggest that novel study-designs are needed to take into account marked patient heterogeneity and to allow for establishing individual clinical drug profiles (Schulz et al., 2016) . In addition, current clinical endpoints completely ignore the patient perspective (social function, quality of life, subjective well-being), and they are usually obtained in short-term studies, which neglect longterm outcomes. The recent discussion about the potential negative effects of long-term antipsychotic treatment on brain structure and the finding that patients with less antipsychotic exposure might have better outcomes urge for the development of new study designs with very long observation periods and new patient-oriented outcomes. These new protocols have
